Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Iris Buchanan-Perry, MD, MSc, FAAPDr. Buchanan serves as a Clinical Instru...
-
Howard Woolley, MASHoward Woolley is a philanthropist with ...
-
Dyspareunia is Associated With Chronic Pain in Premenopausal Women With Sickle Cell DiseaseObjectives: Pain is common in women wit...
-
Sickle Cell Disease Care TeamSickle cell disease (SCD) is an inherit...
-
Sickle Cell Emergency Room Care: From Patients to Providershttps://www.youtube.com/watch?time_conti...
-
Our Healthcare System Abandons Adult Sickle Cell PatientsWhen Janoi Burgess was a child, he thoug...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
